



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



WHI-P97

Item No. 36385

CAS Registry No.: 211555-05-4
Formal Name: 2,6-dibromo-4-[(6,7-dimethoxy-4-quinazoliny)amino]-phenol
Synonym: HY-11067
MF: C₁₆H₁₃Br₂N₃O₃
FW: 455.1
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

WHI-P97 is supplied as a solid. A stock solution may be made by dissolving the WHI-P97 in the solvent of choice, which should be purged with an inert gas. WHI-P97 is soluble in the organic solvent DMSO at a concentration of approximately 3.33 mg/ml.

Description

WHI-P97 is an inhibitor of JAK3 (IC₅₀ = 11 μM).¹ It inhibits leukotriene C₄ (LTC₄) and LTB₄ release, mediated by the high-affinity IgE receptor Fc ε receptor I (FcεRI), from RBL-2H3 mast cells when used at a concentration of 10 μM.² It also inhibits FcεRI-mediated 5-lipoxygenase (5-LO) translocation to the membrane in RBL-2H3 mast cells. *In vivo*, WHI-P97 (40 mg/kg) reduces antigen-induced LTC₄ production in IgE-sensitized mice. It also reduces airway hyperresponsiveness and bronchoalveolar lavage fluid (BALF) eosinophil infiltration in a mouse model of ovalbumin-induced allergic asthma when administered at doses of 12 and 40 mg/kg.

References

1. Sudbeck, E.A., Liu, X.P., Narla, R.K., *et al.* Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. *Clin. Cancer Res.* **5(6)**, 1569-1582 (1999).
2. Malaviya, R., Chen, C.-L., Navara, C., *et al.* Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). *J. Pharmacol. Exp. Ther.* **295(3)**, 912-926 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM